市場調査レポート
商品コード
1433043

医薬品・バイオテクノロジー取引におけるロイヤリティレート

Royalty Rates in Pharmaceutical and Biotechnology Deals

出版日: | 発行: Current Partnering | ページ情報: 英文 500+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.49円
医薬品・バイオテクノロジー取引におけるロイヤリティレート
出版日: 2024年03月01日
発行: Current Partnering
ページ情報: 英文 500+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の医薬品・バイオテクノロジー市場での各種取引におけるロイヤリティレートの設定情況について分析し、全般的な料率の傾向 (2010~2024年) や、技術別・治療領域別の詳細動向、現在開示されている主要なロイヤリティレート条項の基本構造、といった情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

  • ロイヤリティとは何か?
  • ロイヤリティレートの歴史
  • 医薬品・バイオテクノロジーにおけるロイヤリティ
  • ロイヤリティ vs 収益シェア
  • 分析概要

第2章 医薬品・バイオテクノロジーのロイヤリティレートの概要

  • ロイヤリティレートの動向 (2010年~2024年)
  • 収益シェアの計算方法
  • 最近の文献の分析
  • 将来のロイヤリティレート

第3章 医薬品・バイオテクノロジー取引におけるロイヤリティ条項

  • 事業提携契約の構造
  • 典型的なロイヤリティ条項の構造
  • ロイヤリティ条項の事例
    • ケーススタディ (1)
    • ケーススタディ (2)
    • ケーススタディ (3)
    • ケーススタディ (4)

第4章 ロイヤリティレートを積極的に開示する企業

  • ロイヤリティレートの開示に最も積極的な企業

第5章 ロイヤリティレート契約の内訳

  • 取引契約文書内のロイヤリティレートの調査:より深い洞察
  • 取引内訳
  • 取引内訳:取引のロイヤリティレート、企業名別 (A~Z)
  • 取引内訳:取引のロイヤリティレート、治療領域別
  • 取引内訳:取引のロイヤリティレート、契約時の開発段階別
  • 取引内訳:取引のロイヤリティレート、技術の種類別
  • ロイヤリティレートの参考資料
  • ロイヤリティレートの契約文書の例

Wildwood Venturesについて

目次
Product Code: CP2013

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

  • Understand royalty rate trends since 2010
  • Analysis of the structure of royalty clauses with real life case studies
  • Browse collaboration and licensing deals which reveal a royalty rate
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

  • Trends in royalty rates in the biopharma industry since 2010
  • Analysis of royalty rate clause structure
  • Case studies of real-life licensing deals which disclose royalty rates
  • Comprehensive listing of licensing deals which disclose royalty rates since 2010
  • Access to licensing contract documents which disclose royalty rates
  • The leading licensing deals by royalty rate value since 2010
  • Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
  • The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise royalty rates granted?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

  • 1.1. What are royalties?
  • 1.2. History of royalty rates
  • 1.3. Royalties in pharmaceuticals and biotechnology
  • 1.4. Royalties versus revenue share
  • 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

  • 2.1. Trends in royalty rates 2010 - 2024
  • 2.2. How do revenue shares figure?
  • 2.3. A review of recent literature
  • 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

  • 3.1. Partnering agreement structure
  • 3.2. Structure of a typical royalty clause
  • 3.3. Example royalty clauses
    • 3.3.1. Case study 1
    • 3.3.2. Case study 2
    • 3.3.3. Case study 3
    • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

  • 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

  • Explore royalty rates within the deal contract document to gain greater insight
  • Deal Directory
  • Deal Directory - Royalty rates in deals - by company A-Z
  • Deal Directory - Royalty rates in deals - by therapy area
  • Deal Directory - Royalty rates in deals - by stage of development at signing
  • Deal Directory - Royalty rates in deals - by technology type
  • Royalty rate references
  • Example royalty rate deal contract document

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
  • Figure 2: Components of the partnering deal structure
  • Figure 3: Components of the partnering royalty clause
  • Figure 4: Most active companies disclosing royalty rate 2010 - 2024
  • Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies